drugset / Trial / NCT03361436
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
Phase 1
Active not recruiting
15 enrolled
OHSU Knight Cancer Institute
Eisai Inc. · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells.
Timeline
- Start
- 2018-03-19
- Primary completion
- 2023-02-14
- Completion
- 2033-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | Intravenous |